Arm CEO Simon Segars to Keynote at COMPUTEX 2021 on Sparking the World’s Post-Pandemic Recovery
20.5.2021 07:12:00 EEST | Business Wire | Press release
TAITRA (Taiwan External Trade and Development Council) announced today that Arm, the leading technology provider of processor IP, will participate in COMPUTEX 2021 to share an in-depth vision of the future of computing. Simon Segars, will be the keynote speaker of COMPUTEX | Arm CEO Keynote with the topic “Sparking the World’s Post-Pandemic Recovery” at 2 pm on May 31 Taipei Time. Rene Haas, President of Arm’s IP Products Group (IPG), will speak at 3pm on June 2 on #COMPUTEXVirtual regarding “Accelerating Ubiquitous Intelligence”.
Semiconductors are the key to technological innovation and development, and the foundation of all kinds of electronic products. James Huang, TAITRA Chairman, said: "COMPUTEX has grown together with ICT partners for more than 40 years and witnessed the innovation of the technology industry. Especially after the pandemic outbreak last year, we are more aware that technology has the power to reshape the world. This year, we are honored to invite Arm CEO Simon Segars to talk about how technology can accelerate the recovery of the industry after the pandemic and discover the unlimited potential of future computing."
Simon Segars will share his views on how Arm® technology can be used as a remarkable force for good and help with the post-pandemic recovery. The combination of computing in the age of AI will accelerate tackling complex challenges surrounding climate change, security and equitable access to technologies and connectivity.
Though the world has been impacted by the pandemic for more than a year, the digital adoption curve is not slowing. In the "AI Empowerment" session of the COMPUTEX Forum on the afternoon of June 2, Rene Haas will share the unprecedented acceleration of compute trends driven by the growing demands for ubiquitous intelligence across every device on the compute spectrum. He will also explain why the complex AI and ML workloads of today and tomorrow will require more than general-purpose computing.
Arm technology is changing the way people live and businesses operate. Over the past five years, more than 100 billion Arm-based devices have been shipped and reached 70% of the world’s population. The newly released Armv9 architecture will address the global demand for ubiquitous specialized processing with increasingly capable security and artificial intelligence (AI).
Arm will share how its solutions can empower technological innovation in the COMPUTEX CEO Keynote and COMPUTEX FORUM. Join the sessions of Arm CEO Simon Segars, and IPG President Rene Haas, to learn about technology’s role as the epicenter to the post-pandemic recovery and the acceleration of compute trends. To register for Arm’s sessions, please visit the event website: https://virtual.computextaipei.com.tw/events/arm
COMPUTEX 2021 will be presented through #COMPUTEXVirtual Online Exhibition. More information on the COMPUTEX Keynote and forum will be updated regularly on the COMPUTEX official website: http://www.computextaipei.com.tw.
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Hybrid:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. This year, COMPUTEX will launch the "COMPUTEX 2021 Hybrid". As the event organizer, the Taiwan External Trade Development Council (TAITRA) introduces AI computing capabilities to the exhibition to shape COMPUTEX as a global model and aims to deliver an exceptional exhibition experience by presenting the online platform — #COMPUTEXVirtual.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519006026/en/
Contact information
Press:
Ms. Tessa Lin <tessalin@taitra.org.tw>
Ms. Li Chao < lichao@taitra.org.tw>
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 20:09:00 EET | Press release
Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results while favouring its own Google Shopping product, causing sustained and quantifiable commercial damage to PriceRunner over mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom